yusufbaran

yusufbaran's picture
ScienceStream
  • There are no activities to show.

User WAYS points

WAYS Points
0

Member Profile

Academic Level
PhD
Position
Department Chair
Working Sector
Research Institute
Highest Degree
none
Discipline
Not applicable/None
Reseach Topic
Cancer Biology, Science and Technology Policies
Publications

PEER REVIEWED JOURNALS & BOOK CHAPTERS
2005
1. Baran Y*, Gündüz U, Ural AU. Expression of multidrug resistance (MDR1) gene in human promyelocytic leukemia cell line selected with vincristine. Turkish Journal of Cancer, 2005; 35(2): 88-92.
2. Önalan G*, Selam B, Baran Y, Cincik M, Onalan R, Gündüz U, Ural AU, Pabuççu R. Serum and follicular fluid levels of soluble Fas, soluble Fas ligand and apoptosis of luteinized granulosa cells in PCOS patients undergoing IVF. Human Reproduction, 2005; 20(9): 2391-2395.
2006
3. Baran Y*, Gunduz U, Ural AU. Cross-resistance to cytosine arabinoside in human acute myeloid leukemia cells selected for resistance to vincristine. Experimental Oncology, 2006; 28(2): 163-165.
2007
4. Gorduysus M*, Avcu N, Gorduysus O, Pekel A, Baran Y, Avcu F, Ural AU. Cytotoxic Effects of Four Different Endodontic Materials in Human Periodontal Ligament Fibroblasts. Journal of Endodontics, 2007; 33(12): 1450-1454.
5. Ural AU*, Avcu F, Baran Y. Rates of myocardial infarction and coronary artery disease and risk factors in patients treated with radiation therapy for early-stage breast cancer. Cancer, 2007; 110(2): 469-470.
6. Baran Y*, Gunduz U. Kronik Miyelositer Lösemi Genetiği (Genetics of chronic myeloid leukemia). Journal of Turkish Internal Medicine, 2007; 3(2): 50-55
7. Baran Y*, Gur B, Kaya P, Ural AU, Avcu F, Gunduz U. Upregulation of multidrug resistance genes in doxorubicin resistant human acute myelogeneous leukemia cells and reversal of the resistance. Hematology, 2007; 12(6): 511-517.
8. Baran Y*, Ural AU, Gunduz U. Mechanisms of cellular resistance to imatinib in human chronic myeloid leukemia cells. Hematology, 2007; 12(6): 497-503.
9. Baran Y, Salas A, Senkal CE, Gunduz U, Bielawski J, Obeid LM, Ogretmen B*. Alterations of Ceramide/Sphingosine 1-Phosphate Rheostat Involved in the Regulation of Resistance to Imatinib-induced Apoptosis in K562 Human Chronic Myeloid Leukemia Cells. Journal of Biological Chemistry, 2007; 282(15): 10922-10934.
2008
10. Baran Y*, Ural AU, Avcu F, Sarper M, Elçi P, Pekel A. Optimization of Transfection of Green Fluorescent Protein in Pursuing Mesenchymal Stem Cells, In Vivo. Turkish Journal of Hematology, 2008; 25(4): 172-175.
11. Ural AU*, Avcu F, Baran Y. Bisphosphonate treatment and radiotherapy in metastatic breast cancer. Medical Oncology, 2008; 25(3): 350-355.
2009
12. Abaan DO, Mutlu PK, Baran Y, Atalay MC, Gunduz U*. Multidrug Resistance Mediated by MRP1 Gene Overexpression in Breast Cancer Patients. Cancer Investigation, 2009; 27(2): 201-205.
13. Karabulut B, Erten C, Gul MK, Cengiz E, Karaca B, Kucukzeybek Y, Gorumlu G, Atmaca H, Uzunoglu S, Sanli Ua, Baran Y, Uslu R*. Docetaxel/Zoledronic Acid Combination Triggers Apoptosis Synergistically Through Downregulating Antiapoptotic Bcl-2 Protein Level In Hormone-Refractory Prostate Cancer Cells. Cell Biology International, 2009; 33(2): 239-246.
14. Gucluler G, Baran Y*. Docetaxel Enhances the Cytotoxic Effects of Imatinib on Philadelphia Positive Human Chronic Myeloid Leukemia Cells. Hematology, 2009; 14(3): 139-144.
15. Baran Y*, Oztekin C, Bassoy EY. Inhibition of Proteasome by Bortezomib Increased Chemosensitivity of BCR/ABL Positive Human K562 Chronic Myleoid Leukemia Cells to Imatinib. Health, 2009; 1(4): 320-324.
2010
16. Ekiz A, Can G, Gunduz U, Baran Y*. Nilotinib significantly induces apoptosis in imatinib-resistant K562 cells with wild-type BCR-ABL, as effectively as in parental sensitive counterparts. Hematology, 2010; 15(1): 33-38.
17. Goktas S, Baran Y, Ural AU, Yazici S*, Aydur E, Basal S, Avcu F, Pekel A, Dirican B, Beyzadeoglu M. Proteasome Inhibitor Bortezomib Increases Radiation Sensitivity in Androgen Independent Human Prostate Cancer Cells. Urology, 2010; 75(4): 793-798.
18. Baran Y*, Oztekin C, Bassoy EY. Combination of fludarabine and imatinib induces apoptosis synergistically through loss of mitochondrial membrane potential and increases in caspase-3 enzyme activity in human K562 chronic myleloid leukemia cells. Cancer Investigation, 2010; 28(6): 623-628.
19. Ekiz HA, Baran Y*. Therapeutic Applications of Bioactive Sphingolipids in Hematological Malignancies. International Journal of Cancer, 2010; 127(7): 1497-506.
20. Kosova B, Tezcanli B, Ekiz HA, Cakir Z, Selvi N, Dalmizrak A, Kartal M, Gunduz U, Baran Y*. Suppression of STAT5A increases chemotherapeutic sensitivity in imatinib-resistant and imatinib-sensitive K562 cells. Leukemia and Lymphoma, 2010; 51(10): 1895-901.
2011
21. Cakir Z, Saydam G, Sahin F, Baran Y*. The Roles Of Bioactive Sphingolipids In Resveratrol-Induced Apoptosis In HL60 Acute Myeloid Leukemia Cells. Journal Of Cancer Research And Clinical Oncology, 2011; 137: 279–286.
22. Avcı CB, Gunduz C, Baran Y, Sahin F, Yilmaz S, Dogan ZO, Saydam G*. Caffeic Acid Phenethyl Esther Triggers Apoptosis Through Induction of Loss of Mitochondrial Membrane Potential in CCRF-CEM. Journal of Cancer Research and Clinical Oncology, 2011; 137: 41-47.
23. Can G, Ekiz A, Baran Y*. Imatinib induces autophagy through BECLIN-1 and ATG5 genes in chronic myeloid leukemia cells. Hematology, 2011; 16(2): 95-99.
24. Kartal M, Saydam G, Sahin, Baran Y*. Resveratrol triggers apoptosis through regulating ceramide metabolizing genes in human K562 chronic myeloid leukemia cells. Nutrition and Cancer; An International Journal, 2011; 63(4): 637-644.
25. Sanli MG, Turan T, Ekiz HA, Baran Y*. The importance of protein profiling in the diagnosis and treatment of hematologic malignancies. Turkish Journal of Hematology, 2011; 28: 1-14.
26. Mutlu P, Baran Y, Ural AU, Avcu F, Dirican B, Beyzadeoglu M, Gündüz U*. Effect Of Cobalt-60 (Γ Radiation) On Multidrug Resistant Multiple Myeloma Cell Lines. Cell Biology International, 2011; 35(7): 721-5.
27. Salas A, Ponnusamy S, Senkal CE, Meyers MA, Selvam SP, Saddoughi SA, Apohan E, Sentelle RD, Smith C, Gault CR, Obeid LM, El-Shewy HM, Oaks J, Ramasamy S, Marcucci G, Baran Y, Mahajan S, Fernandes D, Stuart RK, Perrotti D, Ogretmen B*. : Sphingosine kinase-1 and sphingosine 1-phosphate receptor 2 mediate Bcr-Abl1 stability and drug resistance by modulation of protein phosphatase 2A. Blood, 2011; 117(22): 5941-5952.
28. Ekiz HA, Baran Y*. Bioactive Sphingolipids in Response to Chemotherapy: A Scope on Leukemias. Anti-Cancer Agents in Medicinal Chemistry, 2011; 11: 385-397.
29. Camgoz A, Gencer EB, Ural AU, Avcu F, Baran Y*. Roles of ceramide synthase and ceramide clearence genes in nilotinib-induced cell death in chronic myeloid leukemia cells. Leukemia and Lymphoma, 2011; 52(8): 1574-84.
30. Firinci F*, Karaman M, Baran Y, Bagriyanik A, Ayyildiz ZA, Kiray M, Kozanoglu I, Yilmaz O, Uzuner N, Karaman O. Mesenchymal Stem Cells Ameliorate The Histopathological Changes in a Murine Model of Chronic Asthma. International Immunopharmacology, 2011; 11(8): 1120-1126.
31. Avcı ÇB, Yılmaz S, Dogan ZO, Saydam G, Dodurga Y, Ekiz HA, Kartal M, Sahin F, Baran Y*, Gunduz C. Quercetin-induced Apoptosis involves increased HTERT enzyme activity of Leukemic Cells. Hematology, 2011; 16(5): 303-307.
32. Baran Y*, Bielawski J, Gunduz U, Ogretmen B. Targeting glucosylceramide synthase sensitizes imatinib-resistant chronic myeloid leukemia cells via endogenous ceramide accumulation. Journal of Cancer Research and Clinical Oncology, 2011; 137(10): 1535-1544.
33. Gencer EB, Ural AU, Avcu F, Baran Y*. A novel mechanism of dasatinib-induced apoptosis in chronic myeloid leukemia; ceramide synthase and ceramide clearance genes. Annals of Hematology, 2011; 90(11): 1265-1275.
34. Avcu F, Avcu N*, Er N, Kansu Ö, Baran Y, Pekel A, Ural AU. The Cytotoxic and Apoptotic-Necrotic Effects of Whitening Materials on Human Gingival Fibroblasts. Clinical Dentistry and Research, 2011; 35(1): 3-11.
35. Baran Y, Zencir S, Çakır Z, Öztürk E, Topçu Z*. Imatinib-induced apoptosis; A possible link to topoisomerase enzyme inhibition. Journal of Clinical Pharmacy and Therapeutics, 2011; 36(6): 673-679.
36. Adan A, Kartal M, Baran Y*. Molecular Biology of Breast Cancer. 2011, Book Chapter, Molecular Approaches to Breast Cancer, ISBN: 978-975-483-928-9.
37. Baran Y*. Critical Decision of the Cell; Survive or Die. 2011, Book Chapter, Cell Death Research Methods Course, ISBN: 978-975-441-349-6.
38. Baran Y*. Gen Transfer Techniques in Cell Death Research. 2011, Book Chapter, Cell Death Research Methods Course, ISBN: 978-975-441-349-6.
39. Gucluler G, Piskin O, Baran Y*. The roles of antiapoptotic sphingosine kinase-1 and glucosylceramide genes in drug induced cell death of MCF-7 breast cancer cells. J BUON, 2011; 16(4): 646-651.
2012
40. Ekiz HA, Can G, Baran Y*. Role of autophagy in the progression and suppression of leukemias. Critical Reviews in Hematology/Oncology, 2012; 81(3): 275-285.
41. Bassoy EY and Baran Y*. Bioactive Sphingolipids in Docetaxel-Induced Apoptosis in Human Prostate Cancer Cells. Biomedicine And Pharmacotherapy, 2012; 66(2): 103-110.
42. Purclutepe O, Iskender G, Kiper HD, Tezcanli B, Selvi N, Avci CB, Kosova B, Sahin F, Baran Y*, Saydam G. Enalapril-Induced Apoptosis of Acute Promyeloctic Leukemia Cells Involves STAT5A. Anticancer Research, 2012; 32: 2885-2894.
43. Ceylan C, Camgoz A, Baran Y*. Macromolecular changes in nilotinib resistant K562 cells; an in vitro study by Fourier transform infrared spectroscopy. Technology in Cancer Research & Treatment, 2012; 11(4): 333-344.
44. Can G, Cakir Z, Kartal M, Gunduz U, Baran Y*. Apoptotic Effects of Resveratrol, a Grape Polyphenol, on Imatinib Sensitive and Resistant K562 Cronic Myeloid Leukemia Cells. Anticancer Research, 2012; 32(7): 2673-8.
45. Baran Y*, Saydam G. Cumulative clinical experience from a decade of use: imatinib as first-line treatment of chronic myeloid leukemia. Journal of Blood Medicine, 2012; 3: 139–150.
46. Bozcuk H, Abali H, Coskun S, Aydıner A, Çinkaya A, Demirkazık A, Özet A, Yolcu A, Balkan A, Çavdar A, Kefeli AÜ, Uluç BO, Atasoy B, Demirkan B, Yalçın B, Eroğlu C, Yalman D, Kılıç D, Tunalı D, Fırat D, Seber E, Üçgül Çavuşoğlu E, Ulukaya E, Kaytan Sağlam E, Tezcanlı E, Eryılmaz E, Dinçbaş FÖ, Telli F, Yumuk F, Başaran G, Çağlar HB, Sönmez H, Yılmaz H, Engin H, Helvacı K, Sönmez K, Koral L, Artaç M, Fuat Eren M, Koçar M, Beyzadeoğlu M, Akın M, Benekli M, Cengiz M, Erman M, Yıldız M, Doğan M, Balkan M, Eraktuğ N, Ünal OÜ, Şencan O, Erpolat Ö, Saip P, Kılıçkap S, Selçuk Seber SO, Paydaş S, Sarıhan S, Kömürcü Ş, Demirkasımoğlu T, Korkmaz T, Yetişyiğit T, Yavuzşen T, Evrensel T, Akman T, Abacıoğlu U, Kefeli U, Egeli Ü, Elgin Y, Baran Y, Bulut Z (Alphabetical order). The correlates of benefit from neoadjuvant chemotherapy before surgery in non-small-cell lung cancer: a metaregression analysis. World Journal of Surgical Oncology, 2012; 10(1): 161-167.
47. Kozanoğlu İ*, Baran Y. The use of molecular diagnostic methods in hematology laboratory. Turkish Clinics, J Hem Onc-Special Topics, 2012; 5(4): 87-93.
2013
48. Gokbulut AA, Yandım MK, Iskender G, Baran Y*. Novel Agents Targeting Bioactive Sphingolipids for the Treatment of Cancer. Current Medicinal Chemistry, 2013; 20: 108-122.
49. Yandım MK, Apohan E, Baran Y*. Therapeutic Potential of Targeting Ceramide/Glucosylceramide Pathway in Cancer. Cancer Chemotherapy and Pharmacology, 2013; 71(1): 13-20.
50. Kozanoglu I, Yandim MK, Cincin ZB, Ozdogu H, Cakmakoglu B, Baran Y*. New indication for therapeutic potential of an old well-known drug (propranolol) for multiple myeloma. Journal of Cancer Research and Clinical Oncology. 2013; 139(2): 327-335.
51. Kaymaz BT, Selvi N, Adan Gokbulut A, Aktan Ç, Gündüz C, Saydam G, Şahin F, Çetintaş VB, Baran Y, Kosova B*. Suppression of STAT5A and STAT5B Chronic Myeloid Leukemia Cells via siRNA and Antisense-Oligonucleotide Applications with the Induction of Apoptosis. American Journal of Blood Research, 2013; 3(1): 58-70.
52. Baran Y*, Ceylan C, Camgoz A. The roles of macromolecules in imatinib resistance of chronic myeloid leukemia cells by Fourier transform infrared spectroscopy. Biomedicine and Pharmacotherapy, 2013; 67: 221-227.
53. Senarisoy M, Canturk P, Zencir S, Baran Y, Topcu Z*. Gossypol interferes with both type I and type II topoisomerases activities without generating strand breaks. Cell Biochemistry and Biophysics, 2013; 66(1): 199-204.
54. Turan T, Sanlı-Mohamed G*, Baran Y*. Changes in Protein Profiles of Multiple Myeloma Cells in Response to Bortezomib. Leukemia and Lymphoma, 2013; 54(5): 1061-1068.
55. Camgoz A, Gencer EB, Ural AU, Baran Y*. Mechanisms responsible for nilotinib resistance in human chronic myeloid leukemia cells and reversal of resistance. Leukemia and Lymphoma, 2013; 54(6): 1279-1287.
56. Sunay O, Can G, Cakir Z, Denek Z, Kozanoğlu I, Erdil G, Mustafa M, Baran Y*. Autologous Rabbit Adipose Tissue Derived Mesenchymal Stem Cells For The Treatment Of Bone Injuries With Distraction Osteogenesis. Cytotherapy, 2013; 15(6): 690-702.
57. Firatligil B, Avci CB, Baran Y*. mir-17 in Imatinib Resistance and Response to Tryosine Kinase Inhibitors in Chronic Myeloid Leukemia Cells. J. BUON, 2013; 18(2):437-441.
58. Gokbulut AA, Apohan E, Baran Y*. Resveratrol and quercetin induced apoptosis of human 232B4 chronic lymphocytic leukemia cells by activation of caspase-3 and cell cycle arrest. Hematology, 2013; 18(3):144-50.
59. Bozkurt S, Özkan T, Özmen F, Baran Y, Sunguroğlu A, Kansu E. The roles of epigenetic modifications of proapoptotic BID and BIM genes in imatinib-resistant chronic myeloid leukemia cells. Hematology, 2013, 18(4): 217-223.
60. Kiper HD, Tezcanli B, Gokbulut AA, Selvi N, Avci CB, Kosova BK, Iskender G, Yandım MK, Gunduz C, Sahin F, Baran Y*, Saydam G. STAT pathway in the regulation of zoledronic acid-induced apoptosis in chronic myeloid leukemia cells. Biomedicine and Pharmacotherapy, 2013; 67(6):527-532.
61. Can G, Akpinar B, Baran Y, Zhivotovsky B, Olsson M*. 5-Fluouracil signaling through a calcium-calmodulin-dependent pathway is required for p53 activation and apoptosis in colon carcinoma cells. Oncogene, 2013; 32(38):4529-4538.
62. Comert M, Baran Y*, Saydam G. Changes in moleculer biology of Chronic Myeloid Leukemia in Tyrosine Kinase Inhibitor era. 2013; (3):191-200. American Journal of Blood Research.
63. Yilmaz AF, Saydam G, Sahin F, Baran Y*. Granulocytic Sarcoma: A Systematic Review. American Journal of Blood Research, 2013; 3(4):265-270.
2014
64. Ömür Ö*, Baran Y, Oral A, Ceylan Y. Fluorine-18-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography For Extranodal Staging Of Non-Hodgkin Lymphoma And Hodgkin Disease. Diagnostic and Interventional Radiology 2014;0(2):185-192.
65. Avci CB, Baran Y*. Micro RNAs in Personilized medicine. Methods in Molecular Biology; miRNomics: MicroRNA Biology and Computational Analysis, Humana Press, 2014, 1107:311-25
66. Aydemir LY, Adan Gokbulut A, Baran Y, Yemenicioglu A*. Bioactive, functional and edible film making properties of different protein isolates from Turkish hazelnut (Corylus avellana L.) meal obtained from oil extraction. Food Hydrocolloids, 2014; 36:130-142.
67. Solmaz S, Gokbulut AA, Cincin B, Ozdogu H, Boga C, Cakmakoglu B, Kozanoglu I, Baran Y*. Therapeutic Potential of Apigenin, a Plant Flavonoid, for Imatinib-Sensitive and Resistant Chronic Myeloid Leukemia Cells. Nutrition and Cancer; An International Journal, 2014; 66(4): 599-612.
68. Celikkanat D, Baran Y*. Comparative development of knowledge-based bioeconomy in the European Union and Turkey. Critical Reviews in Biotechnology, 2014; 34(3): 269-280.
69. Omur O, Baran Y. An Update on Molecular Biology of Thyroid Cancers. Critical Reviews in Oncology/Hematology, 2014; 90(3): 233-252.
70. Cincin ZB, Unlu M, Kıran B, Bireller ES, Baran Y*, Cakmakoglu B*. Molecular Mechanisms of Quercitrin-Induced Apoptosis in Non Small Cell Lung Cancer Cells. Archives of Medical Research, 2014; 45(6): 445-454.
71. Kiraz Y, Unlu M, Kartal Yandim M, Baran Y*. Molecular Biology of Stem Cells. Hematolog, 2014: 4(2); 255-265.
72. Ünlü M, Kiraz Y, Kacı FN, Ozcan MA, Baran Y*. Multidrug Resistance In Chronic Myeloid Leukemia. Turkish Journal of Biology, 2014 38(6); 806-816.
73. Demirer T, Baran Y, Camcı, C, Olgun N, Ozcelik T, Ozet A, Ozkok S, Solak M, Zulfikar B, Gultekin M. National Cancer Policies Workshop Report. By Turkish Academy of Sciences, Cancer Research Group (Book).

2015
74. Cincin ZB, Unlu M, Kıran B, Bireller ES, Baran Y*, Cakmakoglu B*. Apoptotic Effects of Quercitrin in DLD-1 Colon Cancer Cell Lines. Pathology and Oncology Research, 2015: 21; 333-338.
75. Tufekçi O, Yandim MK, Oren H, Irken G, Baran Y*. Targeting FOXM1 Transcription Factor In T-Cell Acute Lymphoblastic Leukemia. Leukemia Research, 2015: 39(3); 342-347.Baran Y*. Drug Resistance in Cancer. Gunce, Official Journal of Turkish Academy of Sciences, 2015; 48: 67-70.
76. Gokbulut AA, Baran Y*. A Novel Natural Product, KL-21, Inhibits Proliferation and Induces Apoptosis in Chronic Lymphocytic Leukemia Cells. In Press, 2015, Turkish Journal of Hematology.
77. Katgı A, Sevindik OG, Gokbulut AA, Ozsan HG, Yuksel F, Solmaz SM, Alacacıoglu I, Ozcan MA, Demirkan F, Baran Y, Piskin O. Nilotinib Does Not Alter the Secretory Funcions of Carotid Artery Endothelıal Cells in a Prothrombotic or Antithrombotic Fashion. In Press, 2015, Clinical and Applied Thrombosis/Hemostasis.
78. Kartal Yandım M, Adan Gokbulut A, Baran Y*. Molecular Mechanisms of Drug Resistance and its Reversal in Cancer. In Press, 2015, Critical Reviews in Biotechnology.
79. Cincin ZB, Unlu M, Kiran B, Bireller ES, Kiraz Y, Baran Y, Cakmakoglu B*. Anti-proliferative, apoptotic and signal transduction effects of hesperidin in non-small cell lung cancer cells. In Press, 2015, Cellular Oncology.
80. Mutlu P, Kiraz Y, Gündüz U, BaranY*. An Update On Molecular Bıology And Drug Resıstance Mechanısms Of Multıple Myeloma, In Press, 2015, Critical Reviews in Biotechnology.
81. Adan A, Baran Y*. The Pleiotropic Effects of Fisetin and Hesperetin on Human Acute Promyelocytic Leukemia Cells Are Mediated through Apoptosis, Cell Cycle Arrest and Alterations in Signaling Networks. Basım Aşamasında, 2015, Tumor Biology.
82. Kaymaz BT, Günel NS, Ceyhan M, Çetintaş VB, Özel B, Yandım MK, Kıpçak S, Aktan Ç, Gökbulut AA, Baran Y, Can BK. Revealing genome-wide mRNA and microRNA expression patterns in leukemic cells highlighted Bhsa-miR-2278 as a tumor suppressor for regain of chemotherapeutic imatinib response due to targeting STAT5A. Basım Aşamasında, 2015, Tumor Biology.
83.
*Corresponding Author

ABSTRACTS PUBLISHED IN INTERNATIONAL CONFERENCES
2004
1- Baran Y, Gündüz U, Ural AU. Investigations of cross-resistance to cytarabine in human promyelocytic leukemia cell line selected for resistance to Vincristine. 6th Balkan Meeting on Human Genetics, August 28-31 2004, Thessaloniki, Greece, p.66.
2005
2- Kars DM, İşeri DÖ, Atalay C, Baran Y, Kaya P, Gündüz U. Investigation of molecular mechanisms of multiple drug resistance in different cell lines and tissue types. The European COST action B16 Symposium on Multidrug Resistance Reversal, May 13-14 2005, Antalya, Turkey, p.35.
3- Avcu F, Ural AU, Baran Y, Sobacı G, Deveci M, Çetin A, Pekel A, Sarper M, Elçi P, Gündüz U. A photodynamic pathway to apoptosis induced by hypericin in human myeloma ARH-77 cell line: Possible relevance to photodynamic therapy. The 47th American Society of Hematology Annual Meeting and Exposition, 2005, p.351B.
2006
4- Baran Y, Şenkal CE, Bielawski J, Öğretmen B, Gündüz U. Overcoming the chemoresistance in human chronic myeloid leukemia K562 cells by siRNA inhibition of sphingosine kinase-1. Haematologica, 11th Congress of European Hematology Association, June 15-18 2006, Amsterdam, Netherlands, p.15.
5- Baran Y, Şenkal CE, Bielawski J, Öğretmen B, Gündüz U. Ceramide glycosylation by glucosyl ceramide synthase inhibits the apoptotic effect imatinib on human K562 and Meg-01 cells. Haematologica, 11th Congress of European Hematology Association, June 15-18 2006, Amsterdam, Netherlands, p.125.
6- Baran Y, Şenkal CE, Bielawski J, Öğretmen B, Gündüz U. The involvement of C:18 ceramide and human longevity assurance genes in imatinib induced apoptosis. Haematologica, 11th Congress of European Hematology Association, June 15-18 2006, Amsterdam, Netherlands, p.124.
7- Baran Y, Ural AU, Öğretmen B, Gündüz U. Multidrug resistance mechanisms in human chronic myeloid leukemia cells. Haematologica, 11th Congress of European Hematology Association, June 15-18 2006, Amsterdam, Netherlands, p.16.
8- Baran Y, Gündüz U, Şenkal BE, Bielawski J, Öğretmen B. The involvement of ceramides in imatinib induced apoptosis and drug resistance. Balkan journal of Medical Genetics, 7th Balkan Meeting on Human Genetics, August 31-September 2 2006, Scopje, Macedonia, p.44.
9- Baran Y, Gündüz U, Ural AU, Öğretmen B. Apoptotic pathways induced by imatinib in sensitive and imatinib-resistant K562 cells. Balkan Journal of Medical Genetics, 7th Balkan Meeting on Human Genetics, August 31-September 2 2006, Scopje, Macedonia, p.127.
10- Baran Y, Gündüz U, Bielawski J, Öğretmen B. Circumventing multi-drug resistance by a combination therapy of imatinib and GCS inhibitor in resistant human chronic myeloid leukemia cells. Balkan J of Medical Genetics, 7th Balkan Meeting on Human Genetics, August 31-September 2 2006, Scopje, Macedonia, p.127.
11- Baran Y, Gündüz U, Öğretmen B. The sequence analyses of imatinib mesylate binding site of Abl kinase domain in sensitive and imatinib-resistant human CML cells. Balkan J of Medical Genetics, 7th Balkan Meeting on Human Genetics, August 31-September 2 2006, Scopje, Macedonia p.128.
12- Baran Y, Salas A, Şenkal CE, Bielawski J, Gündüz U, Obeid LM, Öğretmen B. Alterations of human longevity assurance gene1 (LASS1)/Sphingosine Kinase-1-dependent ceramide generation and metabolism involve in the regulation of imatinib-induced apoptosis and resistance in K562 human chronic myeloid leukemia. The 41st South Eastern Regional Lipid Conference, November 1-3 2006, Cashiers, NC, USA, p.50.
2007
13- Uyuklu T, Ural AU, Sarper M, Avcu F, Baran Y, Elci P, Akar N. A Study of Multiple Drug Resistance Mechanisms Improved Against Bortezomib on Multiple Myeloma Cell Lines In Vitro. The 49th American Society of Hematology Annual Meeting and Exposition, December 8-11 2007, Georgia, Atlanta, USA, p.113B.
2008
14- Avcu F, Ural AU, Sarper M, Uyuklu T, Baran Y, Safali M, Elçi P. The effects of proteasome inhibitor bortezomib on osteoblast differentiation of human bone marrow derived multipotent mesenchymal stem cells, In Vitro. 14th Annual International Society for Cellular Therapy Meeting, May 17-20 2008, Miami, Florida, USA, p.55.
15- Gucluler G, Baran Y. Docetaxel Enhances The Cytotoxic Effects Of Imatinib In Philadelphia Positive Human Chronic Myeloid Leukemia Cells. 32nd World Congress of International Society of Hematology, 19-23 October 2008, Bangkok, Thailand, p.32.
16- Durcan C, Ugur AU, Ferit A, Baran Y. Inhibition Of Ceramide Turnover By Glucosyle Ceramide Inhibitor, PDMP, Increased Dasatinib-Induced Apoptosis. 32nd World Congress of International Society of Hematology, 19-23 October 2008, Bangkok, Thailand, p 108.
17- Bassoy EY, Ozcimen B, Durcan C, Can G, Yusuf B. Inhibition Of Proteasome By Bortezomib Increased Chemosensitivity Of BCR/ABL Positive K562 Human Chronic Myleoid Leukemia Cells To Imatinib. 32nd World Congress of International Society of Hematology, 19-23 October 2008, Bangkok, Thailand, p108.
18- Durcan C, Ural AU, Avcu F, Baran Y. Targeting Conversion Of Apoptotic Ceramide To Antiapoptotic Glucosyle Ceramide Increased Cytotoxic Effects Of Nilotinib In Ph(+) Human Chronic Myeloid Leukemia Cells. 32nd World Congress of International Society of Hematology, 19-23 October 2008, Bangkok, Thailand, p.109.
19- Durcan C, Seher G, Bassoy EY, Can G, Baran Y. Combination Of Fludarabine And Imatinib-Induced Apoptosis Through Loss Of Mitochondrial Membrane Potential And Caspase-3 Enzyme Activity In Human K562 Chronic Myleloid Leukemia Cells. 32nd World Congress of International Society of Hematology, 19-23 October 2008, Bangkok, Thailand, p.33.
2009
20- Baran Y, Güçlüler G. The Involvement Of Glucosyle Ceramide Synthase Gene On Induction Of Apoptosis In Response To Different Anticancer Agents In Mcf-7 Breast Cancer Cells. 8th Balkan Meeting On Human Genetics, 14-17 May 2009, Dubrovnik, Croatia, p.104.
21- Bassoy EY, Gencer EB, Baran Y. The role of LASS1 gene and ceramide accumulation in docetaxel-induced apoptosis in hormone resistant DU-145 and PC-3 Prostate Cancer Cells. 8th Balkan Meeting On Human Genetics, 14-17 May 2009, Dubrovnik, Croatia, p.111.
22- Bassoy EY, Kartal M, Baran Y. The Involvement of Glucosyle Ceramide Synthase in Docetaxel-Induced Apoptosis in Human DU-145 and PC-3 Prostate Cancer Cells. 8th Balkan Meeting On Human Genetics, 14-17 May 2009, Dubrovnik, Croatia, p.108-109.
23- Baran Y, Güçlüler G. The Role Of Sphingosine Kinase-1 Which Converts Apoptotic Sphingosine To Antiapoptotic Sphingosine-1-Phosphate In Docetaxel, Paclitaxel, Doxorubicin, Cyclophosphamide And Tamoxifen Induced Apoptosis In Mcf-7 Breast Cancer Cells. 8th Balkan Meeting On Human Genetics, 14-17 May 2009, Dubrovnik, Croatia, p.110.
24- Baran Y, Bassoy EY, Cakir Z. Inhibition of Conversion of Apoptotic Sphingosine Molecule to Antiapoptotic Sphingosine-1-Phosphate Increased Sensitivity of Prostate Cancer Cells to Docetaxel. 8th Balkan Meeting On Human Genetics, 14-17 May 2009, Dubrovnik, Croatia, p.110.
25- Deveci D, Yüce H, Baran Y. A case Report with Trisomy 8 Mosaicism. 8Pth Balkan Meeting On Human Genetics, 14-17 May 2009, Dubrovnik, Croatia, p.30.
26- Baran Y, Gencer EB, Ural AU, Avcu F. Accumulation of Apoptotic Ceramides Increased Apoptotic Effects of Nilotinib in Philadelphia Positive Meg-01 Cells Synergistically. 14th Congress of European Hematology Association, 04-07 June 2009, Berlin, Germany, p.570.
27- Gencer EB, Ural AU, Avcu F, Baran Y. Targeting Ceramide Metabolism Increased Sensitivity of Philadelphia Positive Chronic Megacaryoblastic Leukemia Cells to Dasatinib. 14th Congress of European Hematology Association, 04-07 June 2009, Berlin, Germany, p.132.
28- Baran Y, Gencer EB, Ural AU, Avcu F. Increasing De Novo Synthesis of Ceramides Increased Nilotinib Induced Apoptosis in Human Meg-01 Chronic Megacaryoblastic Cells. 14th Congress of European Hematology Association, 04-07 June 2009, Berlin, Germany, p.569.
29- Çakır Z, Saydam G, Şahin F, Baran Y. The Effects of Ceramide, Glucosylceramide and Sphingosine 1 Phosphate in Resveratrol Induced Cell Death in HL60 Acute Promyelocytic Leukemia Cells. 14th Congress of European Hematology Association, 04-07 June 2009, Berlin, Germany, p.540-541.
30- Kartal M, Saydam G, Şahin F, Baran Y. Increasing Intracellular Generation or Accumulation of Ceramides Increased Cytotoxic Effects of Resveratrol in Human K562 Chronic Myeloid Leukemia Cells. 14th Congress of European Hematology Association, 04-07 June 2009, Berlin, Germany, p.497.
31- Baran Y, Can G, Ekiz A, Genç Ş. Imatinib Induces Autophagy Through Increasing the Expression Levels of Beclin-1 And Atg-5 Genes in Both Parental Sensitive and Imatinib-Resistant K562 Cells. 14th Congress of European Hematology Association, 04-07 June 2009, Berlin, Germany, p.233.
32- Baran Y, Can G, Ekiz A. Nilotinib Significantly Induces Apoptosis in Imatinib Resistant K562 Cells, As Effectively As in Parental Sensitive Counterparts. 14th Congress of European Hematology Association, 04-07 June 2009, Berlin, Germany, p.343.
33- Gencer EB, Ural AU, Avcu F, Baran Y. Dasatinib induces apoptosis through increasing de novo generation or accumulation of ceramides in human K562 and Meg-01 chronic myeloid leukemia cells. Lipid Signalling and Diseases Congress, 9-15 September 2009, Ortona, Italy, p.46.
34- Baran Y, Güçlüler G. Anticancer Agents Used for the Treatment of Breast Cancer Induces Apoptosis Through Downregulating Antiapoptotic Sphingosine Kinase-1 and Glucosylceramide Synthase Genes in MCF-7 Cells. Lipid Signalling and Diseases Congress, 9-15 September 2009, Ortona, Italy, p.38-39.
35- Çakır Z, Saydam G, Şahin F, Baran Y. Resveratrol Induces Apoptosis Through Induction of Accumulation of Ceramides in Human HL-60 Acute Premyelocytic Cells. Lipid Signalling and Diseases Congress, 9-15 September 2009, Ortona, Italy, p.40.
36- Goktas S, Ural AU, Baran Y, Yazici S, Aydur E, Avcu F, Pekel A, Dirican B. Beyzadeoglu, M. Proteasome Inhibitor Bortezomib Increases Radiation Sensitivity In Androgen Independent Human Prostate Cancer Cells. 104th Annual Meeting of the American-Urological-Association, 25-30 April 2009, Chicago, IL, USA.
2010
37- Can G, Baran Y. Apoptotic Effects Of Resveratrol On Imatinib Sensitve and Resistant Chronic Myeloid Leukemia Cells. 15th Congress of European Hematology Association, 10-13 June 2010, Barcelona, Spain.
38- Baran Y, Camgoz A, Can G. Expression Analysis Of 84 Genes Involved In Different Signalling Pathways Of Cancer In Chronic Myeloid Leukemia Cells In Response To Nilotinib. Inhibition. 15th Congress of European Hematology Association, 10-13 June 2010, Barcelona, Spain.
39- Baran Y, Zincir S, Çakır Z, Ozturk E, Topçu Z. Imatinib-İnduced Apoptosis; A Possible Link To Topoisomerase Enzyme Inhibition. 15th Congress of European Hematology Association, 10-13 June 2010, Barcelona, Spain.
40- Baran Y, Kosova B, Tezcanli B, Ekiz HA, Cakir Z, Selvi N. Suppression of STAT5a Increases Chemotherapeutic Sensitivity in Imatinib-Resistant and Imatinib-Sensitive K562 Cells. 15th Congress of European Hematology Association, 10-13 June 2010, Barcelona, Spain.
41- Baran Y, Kartal M, Can G. Molecular Mechanisms of Resveratrol-Induced Cell Death in K562 Chronic Myeloid Leukemia Cells. 15th Congress of European Hematology Association, 10-13 June 2010, Barcelona, Spain.
42- Baran Y, Cakir Z, Can G, Saydam G, Sahin F. Gene Expression Profiles In Resveratrol Applied Acute Promyelocytic Leukemia Cells. 15th Congress of European Hematology Association, 10-13 June 2010, Barcelona, Spain.
43- Baran Y, Camgoz A, Gencer EB, Ural AU, Avcu F. A Novel Mechanism Of Nilotinib-Induced Apoptosis; Bioactive Sphingolipids. 15th Congress of European Hematology Association, 10-13 June 2010, Barcelona, Spain.
44- Baran Y, Kartal M, Cakir Z, Saydam G, Sahin F. Ceramides Regulate Resveratrol-Induced Apoptosis In Human Acute Promyelocytic And Chronic Myeloid Leukemia Cells. 15th Congress of European Hematology Association, 10-13 June 2010, Barcelona, Spain.
45- Baran Y, Bassoy EY, Cakir Z, Camgoz A, Gencer EB, Kartal M, Can G, Ekiz HA, Gucluler G. Therapeutic Potential of Targeting Sphingolipid Signaling Pathways in Various Types of Cancers. 21st Meeting of European Association for Cancer Research, 26-29 June 2010, Oslo, Norway.
46- Baran Y, Camgoz A, Can G. Changes in Expression Profiles of Apoptosis, Invasion, Metastasis, Angiogenesis, Transcription Factors, Cell Cycle Control and Tumor Supressor Genes in Nilotinib Treated Chronic Myeloid Leukemia Cells. 21st Meeting of European Association for Cancer Research, 26-29 June 2010, Oslo, Norway.
47- Can G, Baran Y. Cytotoxic effects of resveratrol on imatinib sensitive and resistant K562 chronic myeloid leukemia cells. 21st Meeting of the European-Association-for-Cancer-Research 26-29 June 2010, Oslo, Norway.
48- Cakır Z, Baran Y, Can G, Saydam G, Sahin F. Gene Expression Profiles in Resveratrol-Induced Cell Death in Acute Promyelocytic Leukemia Cells. 21st Meeting of European Association for Cancer Research, 26-29 June 2010, Oslo, Norway.
49- Baran Y, Kosova B, Tezcanli B, Ekiz HA, Cakir Z, Selvi N. The roles of STAT transcription Factors in imatinib resistance and sensitivity in BCR/ABL positive chronic myeloid leukemia cells. 21st Meeting of European Association for Cancer Research, 26-29 June 2010, Oslo, Norway.
2011
50- Baran Y, Camgoz A, Ural AU, Avcu F. Molecular Mechanisms Of Nilotinib Resistance And Reversal Of Resistance In Chronic Myeloid Leukemia Cells. 16th Congress of European Hematology Association, 9-12 June 2011, London, UK.
51- Baran Y, Cakir Z. Combination Of Resveratrol And Nilotinib Inhibits Cell Proliferation And Induce Apoptosis Synergistically In Chronic Myeloid Leukemia Cells. 16th Congress of European Hematology Association, 9-12 June 2011, London, UK.
52- Baran Y, Cakir Z. Determination Of Cytotoxic Effects Of Gossypol On Multiple Myeloma Cells. 16th Congress of European Hematology Association, 9-12 June 2011, London, UK.
53- Baran Y, Sunay O, Çakır Z, Can G, Denek Z, Kozanoğlu I, Yılmaz M. Therapeutic Potentials Of Mesenchymal Stem Cells In Bone Defects, The Case Study In Rabbit Tibia. 16th Congress of European Hematology Association, 9-12 June 2011, London, UK.
54- Baran Y, Camgoz A, Ceylan C. Analyses Of Macromolecules In Nilotinib Resistance By Fourier Transform Infrared Spectroscopy. 16th Congress of European Hematology Association, 9-12 June 2011, London, UK.
55- Baran Y, Camgoz A, Ceylan C. The roles of Macromolecules in Imatinib Resistance in Chronic Myeloid Leukemia. 16th Congress of European Hematology Association, 9-12 June 2011, London, UK.
56- Baran Y, Gencer EB, Güçlüler G. Apoptotic Effects of Sunitinib on Multıple Myeloma Cells. 16th Congress of European Hematology Association, 9-12 June 2011, London, UK.
57- Baran Y, Kozanoglu I, Kartal M, Ozdogu H, Sarıalioglu F. A new indication for an old drug; Therapeutic potential of propranolol on human multiple myeloma cells. 16th Congress of European Hematology Association, 9-12 June 2011, London, UK.
58- Firinci F, Karaman M, Baran Y, Bagriyanik A, Ayyildiz ZA, Kiray M, Kozanoglu I, Yilmaz O, Uzuner N, Karaman O. Mesenchymal Stem Cells Ameliorate The Histopathological Changes In A Murine Model Of Chronic Asthma. 30th Congress of the European Academy of Allergy and Clinical Immunology (EAACI), 11-15 June 2011, Istanbul, Turkey.
59- Gökbulut AA, Kartal M, Yaşar M, Baran Y. A Promising New Anticancer Agent, KL-21, Inhibits Proliferation And Cell Cycle Progression And Induces Apoptosis In Chronic Lymphocytic Leukemia Cells But Has No Effect On Healthy Cells. EACR Anticancer Agents Research Congress. 13-16 October 2011, Antalya, Türkiye.
2012
60- Baran Y, Kartal M, Kozanoğlu İ. A Natural Product, Quercetin Enhances The Cytotoxic And Apoptotic Effects Of Dexamethasone On Jurkat Cells. Haematologica, 17th Congress of European Hematology Association, 14-17 June 2012, Amsterdam, Netherlands.
61- Baran Y, Gökbulut AA, Yasar M. A Novel Agent, KL-21, Has Significant Anticancer Potential On Chronic Lymphocytic Leukemia Cells But Not In Healthy Cells. Haematologica, 17th Congress of European Hematology Association, 14-17 June 2012, Amsterdam, Netherlands.
62- Baran Y, Gökbulut AA, Apohan E, Pişkin O, Ozcan MA. Quercetın Induced Apoptosis In 232b4 Chronic Lymphocytic Leukemia Cells. Haematologica, 17th Congress of European Hematology Association, 14-17 June 2012, Amsterdam, Netherlands.
63- Baran Y, Gökbulut AA, Ozcan MA, Pişkin O, Unlü M. Antiproliferative And Apoptotic Effects Of Resveratrol On Chronic Lymphocytic Leukemia Cells. Haematologica, 17th Congress of European Hematology Association, 14-17 June 2012, Amsterdam, Netherlands.
64- Baran Y, Turan T, Sanlı-Mohamed G. Changes In Protein Profiles Of Multiple Myeloma Cells In Response To Bortezomib. Haematologica, 17th Congress of European Hematology Association, 14-17 June 2012, Amsterdam, Netherlands.
65- Saydam G, Kiper HD, Tezcanli B, Selvi N, Avci CB, Baran Y, Kosova B, Sahin F. Zoledronate Induces Apoptosis via Effecting on STAT Pathway in Chronic Myeloid Leukemia Cells. Haematologica, 17th Congress of European Hematology Association, 14-17 June 2012, Amsterdam, Netherlands.
66- Sahin F, Purclutepe O, Kiper HD, Tezcanli B, Selvi N, Avci CB, Baran Y, Kosova B, Saydam G, Enalapril Maleate has Cytotoxic Effect in HL60 Leukemic Cells By Altering STAT Signaling Pathway. Haematologica, 17th Congress of European Hematology Association, 14-17 June 2012, Amsterdam, Netherlands.
67- Kayabasi C, Avci CB, Susluer SY, Balci T, Baran Y, Saydam G, Gunduz C. Autophagic and Apoptotic Effects of Tyrosine Kinase Inhibitors in Myeloid Leukemia: Comparison of Three Generation. 54th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH), 8-11 December 2012 Atlanta, USA.
2013
68- Baran Y, İskender G, Piskin O, Ozcan MA. Determination of the Cytotoxic and Apoptotic Effects of Caffeic Acid Phenethyl Ester and Gossypol in Combination with Fludarabine at a Molecular Level in Acute Lymphoblastic Leukemia Cells. 18th. Congress of European Hematology Association, 13-17 June 2013, Stockholm, Swiss.
69- Baran Y, Gokbulut AA, Cincin ZB, Cakmakoglu B, Kozanoglu I. Changes in Gene Expression Profiles in Response to Apigenin in Imatinib Sensitive and Resistant Chronic Myeloid Leukemia Cells. 18th. Congress of European Hematology Association, 13-17 June 2013, Stockholm, Swiss.
70- Baran Y, Gokbulut AA, Solmaz A, Kozanoglu I, Ozdogu H. Effects of Apigenin on Imatinin-Sensitive And Resistant Chronic Myeloid Leukemia Cells. 18th. Congress of European Hematology Association, 13-17 June 2013, Stockholm, Swiss.
71- Baran Y, Yilmaz S, Cincin ZB, Cakmakoglu B, Kozanoglu I, Ozdogu H. Cytotoxic Effects of Apigenin on Multiple Myeloma Cells. 18th. Congress of European Hematology Association, 13-17 June 2013, Stockholm, Swiss.
72- Baran Y, Yandim MK, Kozanoglu I, Ozdoğu H, Piskin O, Ozcan MA, Saydam G, Sahin F, Avcu F, Ural AU. Diagnostic and Therapeutic Potentials of Expression Levels of Bioactive Sphingolipid Genes in Newly Diagnosed and Drug-Resistant Chronic Myeloid Leukemia Patients. 18th. Congress of European Hematology Association, 13-17 June 2013, Stockholm, Swiss.
73- Katgı A, Gökbulut AA, Sevindik ÖG, Yüksel F, Solmaz SM, Özsan GH, Baran Y, Pişkin O. Effect of Nilotinib on the Function of Carotid Artery Endothelial Cells. 18th. Congress of European Hematology Association, 13-17 June 2013, Stockholm, Swiss.
74- Kozanoglu I, Aygun B, Boga I, Cansun C, Oktar N, Maytalman E, Baran Y, Boga C, Ozdogu H. Immunologically Detection of Bcr/Abl Fusion Protein with Flow Cytometry in K562 Chronic Myeloid Leukemia Cellsand Comparison with RT-PCR Results. 18th. Congress of European Hematology Association, 13-17 June 2013, Stockholm, Swiss.
75- Avcı CB, Kayabasi C, Susluer SY, Balci T, Saydam G, Baran Y, Gunduz C. Ponatinib regulates major signaling pathways in imatinib-resistant chronic myeloid leukemia cells. European Cancer Congress on Reinforcing Multidisciplinarity, 27 September-1 October 2013, Amsterdam, Netherlands.
76- Tufekci O, Yandim MK, Oren H, Irken G, Baran Y. Targeting FOXM1 Transcription
Factor In T-Cell Acute Lymphoblastic Leukemia. 55th Annual Meeting of the American-Society-of-Hematology, 7-10 December 2013, New Orleans, LA, USA.

2014

77- Kozanoglu I, Unver G, Sariturk C, Baran Y, Yeral M, Boga C, Ozdogu H. Comparison of Ishage-Based Cd34 (+) Cell Enumeratİon Protocols On Bd Facs Canto II And Attune Flow Cytometers. 40th Annual Meeting of the European Society for Blood and Marrow Transplantation, 30 March - 2 April 2014, Milan, Italy.
78- Isik S, Karaman M, Baran Y, Kiray M, Caglayan-Sozmen S, Bagriyanik HA, Kozanoglu I, Gokbulut AA, Karaman O, Uzuner N. The effect of mezenchimal stem cells on lung and nasal histopathology and cytokin levels in a murine model of allergic rhinitis. European Academy of Allergy and Clinical Immunology Congress, 7-11 Haziran 2014, Copenhagen, Denmark.
79- Baran Y, Firatligil B, Yandim MK, Kiraz Y, Kozanoglu I, Ozdogu H, Piskin I, Ozcan M, Saydam G, Sahin F, Avcu F, Ural AUU, Unal A. A Novel Biomarker For Drug Resistance In Chronic Myeloid Leukemia: Microrna-17. 5th International Eurasian Hematology Congress, 15-19 October 2014, Antalya, Turkey.
80- Gokbulut AA, Baran Y. Therapeutic Potential of Fisetin, Vitexin and Hesperetin on Chronic Myeloid Leukemia Cells. 5th International Eurasian Hematology Congress, 15-19 October 2014, Antalya, Turkey.
81- Gokbulut AA, Baran Y. Cytotoxic and Apoptotic Effects of Fisetin, Hesperetin and Vitexinon Acute Promyelocytic Leukaemia Cells. 5th International Eurasian Hematology Congress, 15-19 October 2014, Antalya, Turkey.
82- Gokbulut AA, Ogretmen B, Baran Y. Targeting Sphingosine Kinase-1/Sphingosine-1-Phosphate Receptor 2signalling Pathway to Overcome T315i Mutation in 32dcl3 Cells. 5th International Eurasian Hematology Congress, 15-19 October 2014, Antalya, Turkey.
83- Koca D, Hastar N, Baran Y. Inhibition of Jumonji C Domain Containing Histone Demethylases in Acute Myeloid Leukemia. 5th International Eurasian Hematology Congress, 15-19 October 2014, Antalya, Turkey.
84- Kiraz Y, Yandim MK, Kozanoglu I, Ozdogu H, Piskin I, Ozcan M, Saydam G, Sahin F, Avcu F, Ural AU, Unal A, Baran Y. JAK/STAT Signaling Pathway Genes in the Regulation of Tyrosine Kinase Inhibitors Induced and Clinical Process in Chronic Myeloid Leukemia Patients. 5th International Eurasian Hematology Congress, 15-19 October 2014, Antalya, Turkey.
85- Kiraz Y, Neergheen-Bhujun V, Baran Y. Apoptotic Effects of Non-Edible Parts of Punica Granatum on Human Multiple Myeloma Cells. 5th International Eurasian Hematology Congress, 15-19 October 2014, Antalya, Turkey.
86- Yandim MK, Baran Y. Cytotoxic and Cytostatic Effects of Ponatinib on Imatinib-Sensitive and -Resistant Chronic Myeloid Leukemia Cells. 5th International Eurasian Hematology Congress, 15-19 October 2014, Antalya, Turkey.
2015
87- Yandım MK, Kozanoglu I, Ozdogu H, Piskin O, Ozcan MA, Saydam G, Sahin F, Ural AU, Unal A, Baran Y. Correlations Between Expression Levels of Bioactive Sphingolipid Genes and Drug-Ssensitivity and –Resistance in Chronic Myeloid Leukemia (CML) Patients. International Ceramide Conference Sphingolipid Club Joint Meeting, 6-10 Mayıs 2015, Çeşme, Türkiye.
88- Kartal Yandım M, Elmas E, Ceylan C, Baran Y. Antiproliferative and Apoptotic Effects of Ponatinib and its Effects on Macromolecular Changes in Imatinib-Sensitive and –Resistant Chronic Myeloid Leukemia (CML) Cell Lines: A Mechanistic Approach. 20th Congress of European Hematology Association, June 11-14, 2015, Vienna, Austria.
89- Yandım MK, Kozanoglu I, Ozdogu H, Piskin O, Ozcan MA, Saydam G, Sahin F, Ural AU, Unal A, Baran Y. Discovering Alternative Targets in Chronic Myeloid Leukemia (CML): Determination of Expression Levels of Bioactive Sphingolipid Genes in Newly Diagnosed and Drug-Resistant CML Patients. 20th Congress of European Hematology Association, June 11-14, 2015, Vienna, Austria.
90- Gokbulut Adan A, Baran Y. Therapeutic Potential of Fisetin and Identification of Its Mechanisms in Action in Chronic Myeloid Leukemia and Acute Promyelocytic Leukemia Cells. 15th annual FEBS Young Scientists' Forum (YSF) July 2-4, 2015, Berlin, Germany (Poster)
91- Gokbulut Adan A, Baran Y. Therapeutic Potential of Fisetin and Identification of Its Mechanisms in Action in Chronic Myeloid Leukemia and Acute Promyelocytic Leukemia Cells. 40th FEBS Congress, July 4-9, 2015, Berlin, Germany (Poster)
92- Gokbulut Adan A, Ogretmen B, Baran Y. Overcoming nilotinib resistance by specific inhibition of sphingosine-1-phosphate receptor 2/gq/phospholipase c axis in chronic myeloid leukemia. 8th International Ceramide Conference (iCC8) and the Sphingolipid Club joint meeting, May 6-10, 2015, Çeşme, Turkey (Poster)
93- Gokbulut Adan A, Baran Y. A genome-wide analyses of differentially expressed genes and related networks affected by fisetin and hesperetin in chronic myeloid leukemia cells. 20th. Congress of European Hematology Association, 11-14 June 2015, Vienna, Australia (PB1734)
94- Gokbulut Adan A, Ogretmen B, Baran Y. Sphingosine-1-phosphate receptor 2/gq/phospholipase c axis is a novel mechanism to overcome nilotinib resistance in t315i mutation expressing 32dcl3 murine cells. 20th. Congress of European Hematology Association, 11-14 June 2015, Vienna, Australia (E1077)
95- Gokbulut Adan A, Baran Y. The microarray gene profiling analysis of acute promyelocytic leukemia cells in response to fisetin and hesperetin. 20th. Congress of European Hematology Association, 11-14 June 2015, Vienna, Australia (PB1636)
96- Cincin ZB, Kiraz Y, Kıran B, Baran Y, Cakmakoglu B. Molecular mechanisms of quercitrin-induced apoptosis in ECC-1 endometrial cancer cell lines. 5th International Molecular Medicine Congress 20-22 May 2015, İzmir.
97- Rencuzuoglu C, Cincin ZB, Kiraz Y, Baran Y, Cakmakoglu B. Investigation of potential anticarcinogenic effects by corilagin in lung cancer cells. 5th International Molecular Medicine Congress 20-22 May 2015, İzmir.
98- Attar R, Cincin ZB, Bireller ES, Kiraz Y, Baran Y, Cakmakoglu B Investigation of potential anticarcinogenic effects by corilagin in SKOV-3 ovarian cell line carcinoma. 5th International Molecular Medicine Congress 20-22 May 2015, İzmir.
99- Cincin ZB, Kiraz Y, Kıran B, Baran Y, Cakmakoglu B. Anti-proliferative, apoptotic and signal transduction effects of hesperidin in ECC-1 endometrial cancer cells. 5th International Molecular Medicine Congress 20-22 May 2015, İzmir.
100- Kiraz Y, Saydam G, SAhin F, Kozanoglu I, Ozdogu H, Piskin O, Ozcan MA, Avcu F, Ural AU, Unal A, Baran Y. Expression levels of Jak/STAT signaling genes in newly diagnosed drug sensitive and resistant chronic myeloid leukemia patients. 20th. Congress of European Hematology Association, 11-14 June 2015, Vienna, Australia.
101- Kacı N, Kiraz Y, Baran Y. Synergistic apoptotic effects of bortezomib and methylstat on different multiple myeloma cell lines. 20th Congress of European Hematology Association 11-14 June 2015, Vienna, Austria (PB1850).
102-

ABSTRACTS PUBLISHED IN NATIONAL CONFERENCES
1. Ural AU, Gur B, Baran Y, Avcu F, Yilmaz Y, Gunduz U, Yalcin A. Doksorubisine karşı direnç kazandırılmış HL-60 lösemi hattında sitozin-arabinoside karşı gelişen çapraz direnç. 29. Ulusal Türk Hematoloji Kongresi, 25-28 Ekim 2002, Antalya, Türkiye.
2. Baran Y, Gündüz Y. Vinkristin ile seçilmiş HL60 hücrelerinde MDR1 geninin ifadesi. 17. Ulusal Biyokimya Kongresi, 24-27 Haziran 2002, Ankara, Türkiye.
3. Baran Y, Gündüz U, Ural AU. Vinkristine dirençli HL60 hücrelerinin Ara-C’ye karşı çarpraz direnci. 2. Klinik Biyokimya ve Kanser Sempozyumu, 16-18 Nisan 2004, Bursa, Türkiye.
4. Avcu F, Ural AU, Baran Y, Sobacı G, Deveci M, Çetin AT, Pekel A, Sarper M, Elçi P, Gündüz U. İnsan multiple myeloma ARH-77 hücrelerinde hypericin ile indüklenmiş apoptoz yolağının belirlenmesi: fotodinamik tedavi. 31. Ulusal Türk Hematoloji Kongresi, 28 Ekim-2 Kasım 2005, İstanbul, Türkiye.
5. Baran Y, Ural AU, Öğretmen B, Gündüz U. İmatinib uygulanan duyarlı ve dirençli K562 hücrelerinde ilaç dirençlilik mekanizmalari. 32. Ulusal Türk Hematoloji Kongresi, 8-12 Kasım 2006, Antalya, Türkiye.
6. Baran Y, Gündüz U, Öğretmen B. Kronik myeloid lösemi hücrelerinde imatinibin bağlandığı abl kinaz bölgesinin nükleotid dizilerinin belirlenmesi ve ilaç dirençliliği. 32. Ulusal Türk Hematoloji Kongresi, 8-12 Kasım 2006, Antalya, Türkiye.
7. Baran Y, Gündüz U, Öğretmen B. Glukozil seramid sentaz geninin PDMP ile bloke edilmesi ile dirençli kronik myeloid lösemi hücrelerinin imatinibe duyarlılığının arttırılması. 32. Ulusal Türk Hematoloji Kongresi, 8-12 Kasım 2006, Antalya, Türkiye.
8. Baran Y, Gündüz U, Öğretmen B. hLASS1 Geninin imatinib dirençliliğindeki rolü. 32. Ulusal Türk Hematoloji Kongresi, 8-12 Kasım 2006, Antalya, Türkiye.
9. Baran Y, Gündüz U, Öğretmen B. Sfingozin kinaz-1 geninin imatinibin apoptotik etkisi üzerine etkileri. 32. Ulusal Türk Hematoloji Kongresi, 8-12 Kasım 2006, Antalya, Türkiye.
10. Baran Y, Ural AU, Avcu F, Sarper M, Elçi P, Pekel A. Mezankimal Kök Hücrelerin İn Vivo Takibinde Yeşil Floresan Protein Aktarılmasının Optimizasyonu. 33. Ulusal Türk Hematoloji Kongresi, 16-19 Kasım 2007, Antalya, Türkiye.
11. Baran Y, Ural AU, Göktaş S, Avcu F, Aydur E, Uyuklu T, Pekel A, Dırıcan B, Beyzadeoğlu M, Sarper M, Elçı P. Proteazom İnhibitörü Bortezomıb, Radyasyona Dirençli Tümör Hücrelerinde Radyasyon Duyarlılığını Artırmaktadır. 33. Ulusal Türk Hematoloji Kongresi, 16-19 Kasım 2007, Antalya, Türkiye.
12. Ural AU, Baran Y, Avcu F, Çetın T, Uyuklu T, Pekel A, Elçı P, Sarper M. Eritropoetin, Proteazom İnhibitörü Bortezomibin Multıple Myeloma Hücre Dizileri Üzerindeki Antiproliferatif Etkisini Engellemektedir. 33. Ulusal Türk Hematoloji Kongresi, 16-19 Kasım 2007, Antalya, Türkiye.
13. Avcu F, Ural AU, Sarper M, Uyuklu T, Baran Y, Safalı M, Elçi P. Proteazom İnhibitörü Bortezomibin Mezankimal Kök Hücreler Üzerine Osteoblastik Farklılaşma Etkilerinin İncelenmesi. 33. Ulusal Türk Hematoloji Kongresi, 16-19 Kasım 2007, Antalya, Türkiye.
14. Uyuklu T, Ural AU, Sarper M, Avcu F, Baran Y, Elçi P, Akar N. İn Vitro Koşullarda Multiple Myeloma Hücre Dizilerinde Bortezomıbe Karşı Geliştirilen Çoklu İlaç Direnç Mekanizmalarının İncelenmesi. 33. Ulusal Türk Hematoloji Kongresi, 16-19 Kasım 2007, Antalya, Türkiye.
15. Baran Y, Durcan C, Ural AU, Avcu F. Kronik Miyeloid Löseminin Daha Etkin Tedavisi Amacıyla BCR/ABL Aktivitesinin Dasatinib İle Engellenmesinin Yanısıra Seramid Sentezinin Hedeflenmesi. 34. Ulusal Türk Hematoloji Kongresi, 8-11 Ekim 2008, İzmir, Türkiye.
16. Baran Y, Durcan C, Ural AU, Avcu F. Nilotinib/C8 Seramid Kombinasyonun İnsan K562 Kronik Miyeloid Lösemi Hücreleri Üzerine Sinerjistik Apoptotik Etkileri. 34. Ulusal Türk Hematoloji Kongresi, 8-11 Ekim 2008, İzmir, Türkiye.
17. Mutlu P, Baran Y, Ural AU, Gündüz U. Kobalt 60 Gama Radyasyonunun Kemoterapiye Dirençli Multipl Myeloma Hücre Hatları Üzerine Etkisi. 34. Ulusal Türk Hematoloji Kongresi, 8-11 Ekim 2008, İzmir, Türkiye.
18. Baran Y. Drug Resistance in Chronic Myeloid Leukemia, Cellular Perspective. 34. Ulusal Türk Hematoloji Kongresi, 8-11 Ekim 2008, İzmir, Türkiye.
19. Baran Y. Kronik myeloid lösemide moleküler moniterizasyon: Nasıl ve ne zaman? 35. Ulusal Türk Hematoloji Kongresi, 7-10 Ekim 2009, Antalya, Türkiye.
20. Baran Y, Ceylan Ç. İmatinib Dirençliliğinin K562 Hücreleri Üzerindeki Etkilerinin Fourier Transform İnfrared Spektroskopi (FTIR) Yöntemiyle İncelenmesi. 35. Ulusal Türk Hematoloji Kongresi, 7-10 Ekim 2009, Antalya, Türkiye.
21. Kartal M, Baran Y. Resveratrol Kronik Miyeloid Lösemi Hücrelerinde BCR/ABL Onkogenini Doza Bağımlı Olarak Baskılayarak Apoptozu Tetiklemektedir. 35. Ulusal Hematoloji Kongresi, 7-10 Ekim 2009, Antalya.
22. Kartal M, Saydam G, ŞAhin F, Baran Y. Hücre İçi Seramid Birikiminin Biyokimyasal Yöntemlerle Sağlanması ile Resveratrolün Apoptotik Etkilerinin K562 Kronik Miyeloid Lösemi Hücrelerinde Arttırılması. 35. Ulusal Hematoloji Kongresi, 7-10 Ekim 2009, Antalya.
23. Gencer EB, Ural AU, Avcu F, Baran Y. BCR/ABL pozitif K562 ve MEG-01 hücrelerinde seramid metabolizmasının apoptotik seramidin birikimini tetikleyecek şekilde hedeflenmesi ile dasatinibin apoptotik etkilerinin arttırılması. 35. Ulusal Hematoloji Kongresi, 7-10 Ekim 2009, Antalya.
24. Baran Y, Gencer EB, Camgoz A, Ural AU, Avcu F. K562 hücrelerinde nilotinib-aracılı apoptozda seramid metabolizması genlerinin rolü. 35. Ulusal Hematoloji Kongresi, 7-10 Ekim 2009, Antalya.
25. Baran Y, Gencer EB, Camgoz A, Ural AU, Avcu F. Nilotinibin MEG-01 hücrelerinde tetiklediği hücresel ölümlerde yeni bir mekanizma; apoptotik lass genlerinin indüklenmesi ve antiapoptotik sfingozin kinaz-1 geninin baskılanması. 35. Ulusal Hematoloji Kongresi, 7-10 Ekim 2009, Antalya.
26. Baran Y, Zencir S, Çakır Z, Öztürk E, Topçu Z. Yeni Bir Mekanizma Olarak İmatinibin Tetiklediği Hücresel Ölümlerde Topoizomeraz-I Enzim Aktivitesi Değişimi. 35. Ulusal Hematoloji Kongresi, 7-10 Ekim 2009, Antalya.
27. Çakır Z, Saydam G, Şahin F, Baran Y. Resveratrolün HL60 Akut Promiyelositik Lösemi Hücrelerinde Tetiklediği Apoptozda Yeni Bir Mekanizma; Sfingolipidler 35. Ulusal Hematoloji Kongresi, 7-10 Ekim 2009, Antalya
28. Baran Y. Kanser Hücre Kültürlerinde İlaç Duyarlılığında Genetik Etkenler. 5. Ulusal Onkolojik Araştırmalar Çalıştayı ve Kursları, 10-15 Kasım 2009, Antalya, Türkiye.
29. Camgöz A, Gencer EB, Ural AU, Avcu F, Baran Y. Bcr/Abl Pozitif Kronik Miyeloid Lösemi Hücrelerinde Nilotinibe Karşı Direnç Geliştirilmesi ve Olası Direnç Mekanizmalarının Araştırılması. 36. Ulusal Türk Hematoloji Kongresi, 3-7 Kasım 2010, Antalya, Türkiye.
30. Baran Y, Can G, Çakır Z, Kartal M. Resveratrolün İmatinib'e Duyarlı ve Dirençli Kronik Myeloid Lösemi Hücreleri Üzerine Sitotoksik ve Apoptotik Etkileri. 36. Ulusal Türk Hematoloji Kongresi, 3-7 Kasım 2010, Antalya, Türkiye.
31. Baran Y, Sunay Ö, Çakır Z, Can G, Denek Z, Kozanoğlu İ, Yılmaz M. Kemik Hasarlarının Tedavisinde Mezenkimal Kök Hücrelerin Terapötik Potansiyelleri; Tavşan Tibiasında Deneysel Çalışma. 36. Ulusal Türk Hematoloji Kongresi, 3-7 Kasım 2010, Antalya, Türkiye.
32. Baran Y, Can G, Çakır Z, Kozanoğlu İ. Mezenkimal Kök Hücrelerin Takibinde Kullanılan Yeşil Floresan Protein Geninin Hücrelere Aktarımının Optimizasyonu. 36. Ulusal Türk Hematoloji Kongresi, 3-7 Kasım 2010, Antalya, Türkiye.
33. Gencer EB, Güçlüler G, Öztekin C, Baran Y. Sunitinib'in U266 Multipl Miyelom Hücreleri Üzerine Apoptotik Etkileri. 36. Ulusal Türk Hematoloji Kongresi, 3-7 Kasım 2010, Antalya, Türkiye.
34. Camgöz A, Can G, Baran Y. Nilotinib Uygulanan Kronik Miyeloid Lösemi Hücrelerinde Apoptoz, Anjiogenez, Metastaz, İnvazyon, Transkripsiyon Faktörleri, Hücre Döngüsü ve Tümör Baskılayıcı Genlerin Ekspresyon Düzeylerinin QPCR Yöntemi ile Belirlenmesi. 36. Ulusal Türk Hematoloji Kongresi, 3-7 Kasım 2010, Antalya, Türkiye.
35. Kartal M, Kozanoğlu İ, Özdogu H, Sarıalioglu F, Baran Y. Eski Bir İlaç, Yeni Bir Yaklaşım: Propranolol’un U266 Multiple Miyelom Hücreleri Üzerine Apoptotik Etkileri. 36. Ulusal Hematoloji Kongresi, 3-7 Kasım 2010, Antalya.
36. Kartal M, Can G, Saydam G, Şahin F, Baran Y. Resveratrolün Kronik Miyeloid Lösemi Hücrelerinde Kanser Sinyal İleti Yolağı Genleri Üzerine Etkileri. 36. Ulusal Hematoloji Kongresi, 3-7 Kasım 2010, Antalya.
37. Çakır Z, Can G, Saydam G, Şahin F, Baran Y. Resveratrol Uygulanan Akut Myeloid Lösemi Hücrelerinde (HL60) Gen Ekspresyon Profilleri. 36. Ulusal Hematoloji Kongresi, 3-7 Kasım 2010, Antalya.
38. Çakır Z, Saydam G, Şahin F, Baran Y. Resveratrolün HL60 Akut Promiyelositik Lösemi Hücrelerinde Tetiklediği Apoptozda Yeni Bir Mekanizma; Sfingolipidler. III. Multidisipliner Kanser Arastima Sempozyumu 14 -17 Mart 2010, Bursa.
39. Gökbulut Adan A, Ünlü M, Baran Z, Pişkin Ö, Özcan M.A, Baran Y. Resveratrolün Kronik Lenfositik Lösemi hücreleri üzerine antiproliferatif ve apoptotic etkileri. 37. Ulusal Türk Hematoloji Kongresi, 19-22 Ekim 2011, Ankara, Türkiye.
40. Apohan E, Gökbulut Adan A, Pişkin Ö, Özcan MA, Baran Y. Kuersetin'in 232B4 Kronik Lenfositik Lösemi Hücreleri Üzerine Sitotoksik ve Apoptotik Etkileri. 37. Ulusal Türk Hematoloji Kongresi, 19-22 Ekim 2011, Ankara, Türkiye.
41. Baran Y, Camgöz A, Gencer EB, Ural AU, Avcu F. Bcr/Abl Onkogeninin Bilinen Tek Regülatör Mekanizması olan Sfingozin Kinaz-1 ve Glukozil Seramid Sentaz Genlerinin Hedeflenerek Kronik Miyeloid Lösemi'de Nilotinib Dirençliliğinin Geri Çevrilmesi. 37. Ulusal Türk Hematoloji Kongresi, 19-22 Ekim 2011, Ankara, Türkiye.
42. Turan T, Şanlı Mohamed G, Baran Y. Bortezomib Uygulanan Multipl Miyelom Hücrelerinin Protein Profillerindeki Değişimlerin Proteomiks Yaklaşım ile Belirlenmesi. 37. Ulusal Türk Hematoloji Kongresi, 19-22 Ekim 2011, Ankara, Türkiye.
43. Kartal Yandım M, Piskin O, Ozcan MA, Saydam G, Şahin F, Kozanoglu I, Ozdogu H, Avcu F, Ural AU, Baran Y. Yeni Tanılı ve Dirençli Kronik Miyeloid Lösemi Hastalarında Biyoaktif Sfingolipid Genlerinin Ekspresyon Seviyelerinin Belirlenmesi. IV. Multidisipliner Kanser Araştırma Kongresi, 13-16 Aralık 2012, Bursa, Türkiye.
44. Kozanoglu I, Kartal Yandım M, Cincin ZB, Ozdogu H, Cakmakoglu B, Baran Y.“Eski Bir İlaç, Yeni Bir Yaklaşım: Dideral’in Multipl Miyelom Hücrelerinin Üzerine Apoptotik Etkileri ve NF-kB Sinyal Yolağı Üzerine Etkileri”. IV. Multidisipliner Kanser Araştırma Kongresi, 13-16 Aralık 2012, Bursa.
45. Baran Y, Aydemir LY, Gencer EB, Kartal M, Yemenicioglu A. Mercimek Protein Ekstraktının Akut Miyeloid Lösemi Hücreleri Üzerine Etkileri. IV. Multidisipliner Kanser Araştırma Kongresi, 13-16 Aralık 2012, Bursa.
46. Gokbulut Adan A, Yaşar M, Baran Y. Antiproliferative and apoptotic effcts of Potansiyel bir Antikarsinojenik Ajan olan KL-21'in Kronik Lenfositik Lösemi Hücreleri Üzerine Antiproliferatif ve Apoptotik Etkileri. IV. Multidisipliner Kanser Araştırma Kongresi, 13-16 Aralık 2012, Bursa.
47. Gökbulut Adan A, Solmaz S, Kozanoğlu İ, Boğa C, Özdoğu H, Baran Y. İmatinib Duyarlı ve İmatinib Dirençli Kronik Miyeloid Lösemi Hücreleri Üzerinde Apigenin'in Etkileri. IV. Multidisipliner Kanser Araştırma Kongresi, 13-16 Aralık 2012, Bursa.
48. Baran Y, Aydemir LY, Gencer EB, Kartal M, Yemenicioglu A. Mercimek Protein Ekstraktının Akut Miyeloid Lösemi Hücreleri Üzerine Etkileri. 38. Ulusal Hematoloji Kongresi, 31 Ekim-3 Kasım 2012, Antalya.
49. Baran Y, Geylani C, Çakır Z, Kozanoğlu İ. Mezenkimal Kök Hücrelerin İn Vitro ve İn Vivo Takibi İçin Hücrelere Yeşil Floresan Protein Kodlayan Genin Aktarımının Optimizasyonu. 7. Ulusal Kemik İliği Transplantasyonu ve Kök Hücre Tedavileri Kongresi, 8-10 Mart 2012, Antalya, Türkiye.
50. Kayabaşı Ç, Avcı Biray Ç, Süslüer Yılmaz S, Balcı T, Baran Y, Saydam G, Gündüz C. Kronik Miyeloid Lösemi ve Lösemi Kök Hücre Hatlarında 3 Nesil Tirozin Kinaz İnhibitörlerinin Etkileri: Apoptoz, Otofaji ve miRNA Değişimleri. 38. Ulusal Türk Hematoloji Kongresi, 31 Ekim-3 Kasım 2012, Antalya, Türkiye.
51. Baran Y, Fıratlıgil B. Kronik Miyeloid Lösemi'de İmatinib Direncinde ve Tirozin Kinaz İnhibitörlerine Verilen Hücresel Yanıtta miR-17 MikroRNA'sının Rolü. 38. Ulusal Türk Hematoloji Kongresi, 31 Ekim-3 Kasım 2012, Antalya, Türkiye.
52. Durmuş A, Yılmaz M, Yandım Kartal M, Muhammet YA, Baran Y, İkbal M. Nadir Bir Prezentasyon Olarak Herediter Kronik Nötrofili Ailesi. 38. Ulusal Türk Hematoloji Kongresi, 31 Ekim-3 Kasım 2012, Antalya, Türkiye.
53. İskender G, Pişkin Ö, Özcan MA, Baran Y. Fludarabin'in Kafeik Asit Fenetil Ester veya Gosipol ile Kombinasyonunun Akut Lenfoblastik Lösemi Hücreleri Üzerine Sitotoksik ve Apoptotik Etkilerinin Moleküler Düzeyde Belirlenmesi. 38. Ulusal Türk Hematoloji Kongresi, 31 Ekim-3 Kasım 2012, Antalya, Türkiye.
54. Yılmaz S, Kozanoğlu İ, Özdoğu H, Baran Y. Apigenin'in Multipl Miyelom Hücreleri Üzerine Sitotoksik Etkileri. 38. Ulusal Türk Hematoloji Kongresi, 31 Ekim-3 Kasım 2012, Antalya, Türkiye.
55. Baran Y, Aydemir LY, Gencer EB, Yandım Kartal M, Yemenicioğlu A. Mercimek Protein Ekstraktının Akut Miyeloid Lösemi Hücreleri Üzerine Etkileri. 38. Ulusal Türk Hematoloji Kongresi, 31 Ekim-3 Kasım 2012, Antalya, Türkiye.
56. Kozanoğlu İ, Kartal Yandım M, Cincin ZB, Özdoğu H, Çakmakoğlu B, Baran Y. Propranololün Multipl Miyelom Hücreleri Üzerine Apoptotik Etkilerinin Genetik Mekanizmaları 38. Ulusal Hematoloji Kongresi, 31 Ekim-3 Kasım 2012, Antalya, Türkiye.
57. Tüfekçi Ö, Kartal Yandım M, Ören H, İrken G, Baran Y. T Hücreli Akut Lenfoblastik Löseminin Tedavisinde FOXM1 Transkripsiyon Faktörünün Hedeflenmesi. 38. Ulusal Hematoloji Kongresi, 31 Ekim-3 Kasım 2012, Antalya, Tüykiye.
58. Durmuş A, Yılmaz M, Kartal Yandım M, Alp MY, Baran Y, İkbal M. Nadir Bir Prezentasyon Olarak Herediter Kronik Nötrofili Ailesi. 38. Ulusal Hematoloji Kongresi, 31 Ekim-3 Kasım 2012, Antalya, Türkiye.
59. Kartal Yandım M, Pişkin Ö, Özcan MA, Saydam G, Şahin F, Kozanoğlu İ, Özdoğu H, Avcu F, Ural AU, Baran Y. Yeni Tanı ve Dirençli Kronik Miyeloid Lösemi Hastalarında Biyoaktif Sfingolipid Genlerinin Ekspresyon Düzeylerinin Belirlenmesi ve Hastalığın Seyrine Etkileri. 38. Ulusal Hematoloji Kongresi, 31 Ekim-3 Kasım 2012, Antalya, Türkiye.
60. Gökbulut Adan A, Yasar M, Baran Y. Potansiyel bir Antikarsinojenik Ajan olan KL-21'in Kronik Lenfositik Lösemi Hücreleri Üzerine Antiproliferatif ve Apoptotik Etkileri. 38. Ulusal Türk Hematoloji Kongresi, 31 Ekim-3 Kasım 2012, Antalya, Türkiye.
61. Solmaz S, Gökbulut Adan A, Kozanoğlu İ, Boğa C, Özdoğu H, Baran Y. İmatinib Duyarlı ve İmatinib Dirençli Kronik Miyeloid Lösemi Hücreleri Üzerinde Apigenin'in Etkileri. 38. Ulusal Türk Hematoloji Kongresi, 31 Ekim-3 Kasım 2012, Antalya, Türkiye.
62. Kartal Yandım M, Kozanoğlu İ, Özdoğu H, Pişkin Ö, Özcan MA, Saydam G, Şahin F, Avcu F, Ural AU, Baran Y. Yeni Tanı ve Dirençli Kronik Miyeliod Lösemi Hastalarında Biyoaktif Sfingolipid Genlerinin Ekspresyon Düzeylerinin Belirlenmesi ve Hastalığın Seyrine Etkileri. 39. Ulusal Hematoloji Kongresi, 23-26 Ekim 2013, Antalya, Türkiye.
63. Adan Gökbulut A, Baran Y. Fisetin, hesperetin ve viteksinin kronik myeloid lösemi hücreleri üzerine etkileri. 39. Ulusal Hematoloji Kongresi, 23-26 Ekim 2013, Antalya, Türkiye.
64. Adan Gökbulut A, Baran Y. Fisetin, hesperetin ve viteksinin akut premyelositik lösemi hücreleri üzerine apoptotik ve sitotoksik etkileri. 39. Ulusal Hematoloji Kongresi, 23-26 Ekim 2013, Antalya, Türkiye.
65. Adan Gökbulut A, Solmaz S, Cincin B, Ozdogu H, Boga C, Cakmakoğlu B, Aygun B, Kozanoglu I, Baran Y. Apigenin ile Muamele Edilen İmatinib Duyarlı Ve İmatinib Dirençli̇ Kroni̇k Myeloid Lösemi Hücrelerinin Gen Ekspresyonundaki̇ Değişikliklerin Saptanması. 39. Ulusal Hematoloji Kongresi, 23-26 Ekim 2013, Antalya, Türkiye.
66. Koca D, Haştar N, Ünlü M, Oppermann U, Baran Y. Akut Miyeloid Lösemide Jumonji C Domain İçeren Histon Demetilazların Terapötik Potansiyellerinin Belirlenmesi. 39. Ulusal Hematoloji Kongresi, 23-26 Ekim 2013, Antalya, Türkiye.
67. Kayabaşı Ç, Avcı ÇB, Süslüer SY, Balcı T, Yelken BÖ, Çalışkan C, Bakiye Göker B, Saydam G, Baran Y, Gündüz C. Ponatinibin NF-KB ve MAPK Sinyal Yolakları Üzerindeki Etkilerinin İmatinibe Dirençli ve Duyarli Kronik Miyeloid Lösemi Hücrelerinde Araştırılması. 39. Ulusal Hematoloji Kongresi, 23-26 Ekim 2013, Antalya, Türkiye.
68. Aygün B, Kozanoğlu İ, Baran Y, Maytalman E, Üstündağ N, Siber C, Boğa İ, Boğa C, Özdoğu H. Bcr/Abl Füzyon Protei̇ninin K562 Hücre Serisinde In Vitro Olarak Immunolojik Metodla Akım Sitometri̇de Tayini Ve Sonuçların Rt-Pcr ile Karşılaştırılması. 39. Ulusal Hematoloji Kongresi, 23-26 Ekim 2013, Antalya, Türkiye.
69. Aydemir LY, Adan A, Baran Y, Yemenicioğlu A. Fındık küspesinden gıda, ilaç ve kozmetik alanında kullanılabilecek katma değeri yüksek protein izolatı üretimi. II. Uluslararası Gıda Arge Proje Proje Pazarı, 2013, İzmir, Türkiye.
70. Aydemir LY, Adan A, Baran Y, Yemenicioğlu A. Fındık küspesinden gıda, ilaç ve kozmetik alanında kullanılabilecek katma değeri yüksek protein izolatı üretimi. Türkiye İnovasyon Haftası, 28-30 Kasım 2013, İzmir, Türkiye.
71. İskender G, Baran Y. Gosipol’ün Multipl Myelom Hücreleri Üzerine Sitotoksik ve Apoptotik Etkilerinin Moleküler Düzeyde Belirlenmesi. 39. Ulusal Hematoloji Kongresi, 23-26 Ekim 2013, Antalya, Türkiye.
72. Eroglu P, Kartal Yandım M, Gokbulut AA, Kiraz Y, Kozanoglu I, Baran Y. Mezenkimal Kök Hücrelerin Yaşlanmanın Olumsuz Etkilerini Azaltma Potansiyellerinin Moleküler, Histomorfolojik ve İmmnuhistokimyasal Yöntemlerle Belirlenmesi: İn vivo Deneysel Bir Çalışma 40. Ulusal Hematoloji Kongresi, 22-25 Ekim 2014, Antalya, Türkiye.
73. Kartal Yandım M, Kozanoğlu İ, Özdoğu H, Pişkin Ö, Özcan MA, Saydam G, Şahin F, Avcu F, Ural AU, Unal A, Baran Y. Yeni Tanılı ve Dirençli Kronik Miyeloid Lösemi (KML) Hastalarında Seramid Metabolize Eden Genlerin Ekspresyon Düzeyleri: KML’de Yeni Hedef Bulma Girişimleri. 40. Ulusal Hematoloji Kongresi, 22-25 Ekim 2014, Antalya, Türkiye.
74. Işık S, Uzuner N, Karaman M, Karaman Ö, Kıray M, Kozanoğlu İ, Bağrıyanık HA, Arıkan Ayyıldız Z, Kartal Yandım M, Baran Y. Deneysel Olarak Oluşturulan Bronşiolitis Obliterans Tedavisinde Mezenkimal Kök Hücrenin Yeri. 40. Ulusal Hematoloji Kongresi, 22-25 Ekim 2014, Antalya, Türkiye.
75. Baran Y, Fıratlıgil B, Kartal Yandım M, Kiraz Y, Kozanoğlu İ, Özdoğu H, Pişkin Ö, Özcan MA, Saydam G, Şahin F, Avcu F, Ural AU, Unal A. Kronik Miyeloid Lösemi’de İlaç Dirençliliği ve Duyarlılığında Yeni Bir Belirteç; MikroRNA-17. 40. Ulusal Hematoloji Kongresi, 22-25 Ekim 2014, Antalya, Türkiye.

Prizes / Awards

AWARDS
2015
1. Young Scientist Project Support Award, Guven Hospital, 7th Aysun Ahmet Küçükel Medicine Awards.
2. Best Study Award, IInd Experimental Hematology Congress with International Participation
2014
3. 2014 FABED Eser Tumen Outstanding Achievement Award, by Istanbul Technical University, Fevzi Akkaya Scientific Activities Support Programme
4. Outstanding Young Scientist Award, Science Heros Association
5. Outstanding Labor Scientist Award, Experimental Hematology Association
6. The Best Study Award, 6th National Congress of Pediatric Respiratory Diseases and Cystic Fibrosis
7. Experimental Hematology Award, Experimental Hematology Congress
8. Best Poster Award, 9th National Pediatric Allergy and Asthma Congress
9. Travel Grant Award, 19th Congress of European Hematology Association
10. Honourable Mention Award, Experimental Hematology Congress
11. Honourable Mention Award (II.nd Best Oral Presentation Award), I.st International Stem Cell and Cellular Therapy Congress.
12. Honourable Mention Award (III.rd Best Oral Presentation Award), I.st International Stem Cell and Cellular Therapy Congress.

2013
13. 2013 Young Scientist Award, by World Economic Forum
Dr. Yusuf Baran has been selected as a 2013 Young Scientist. This honour is bestowed by the World Economic Forum each year to recognize the most distinguished science leaders under the age of 40, nominated from around the world. Dr Baran’s selection is in recognition of his record of scientific excellence, his commitment to society and potential to contribute to transforming the world through his scientific knowledge.
14. Outstanding Young Person of Turkey in Scientific Leadership, by Junior Chamber International. Junior Chamber International Junior Chamber International is a membership-based nonprofit organization of more than 200,000 young people from 118 countries around the world.
15. Global Young Academy Membership, by Global Young Academy.
16. Invited Speaker, III. Baku International Humanitarium Forum, Baku, Republic of Azarbaijan.
17. The Best Hypothesis Award, International Symposium on Cancer Nanomedicine
18. Experimental Hematology Award, Turkish Society of Hematology.
19. First Prize, II International Food R&D Brokerage Event.
20. Travel Grant, by European Hematology Association.
21. Best Study Award, by Turkish Society of Pediatric Hematology.
2012
22. Cancer Researcher of the Year Award, by Society of Molecular Cancer Research
23. Turkish Blood Science Award, by Turkish Society of Hematology
24. Science Encouragement Award, by Kocaeli University
25. Travel Grant, by European Society of Hematology
2011
26. Experimental Hematology Award, by Turkish Society of Hematology
27. Young Participant Award, by Turkish Society of Hematology. (to our study with Aysun Adan Gökbulut)
28. Best Poster Award, 1st International Conference on Stem Cell Research and Applications, Erciyes University.
29. Süreyya Tahsin Aygün, Best Poster Award, by Society of Regenerative Medicine and Cellular Therapy.
30. Travel Grant, by European Society of Hematology
2010
31. Outstanding Young Scientist Award, by Turkish Academy of Sciences.
32. Special Award of Society of Molecular Cancer Research, by Society of Molecular Cancer Research.
33. Travel Grant, by European Society of Hematology
34. Meeting Bursary Award, by European Association of Cancer Research
35. Best Oral Presentation Award, by Turkish Society of Hematology.
36. Young Researcher Travel Grant Award, by Turkish Society of Hematology.
37. Best Poster Award in Basic Immunology, by Turkish Society of Allergy and Clinical Immunology.
38. Second Prize in Experimental Studies, by Turkish Society of Plastic, Reconstructive and Esthetic.
2009
39. Best Hypothesis Award in Basic Oncology, by Turkish Society of Oncology Group
40. Experimental Hematology Award, by Turkish Society of Hematology.
41. Travel Grant, by European Hematology Association.
42. Young Participant Award, by Turkish Society of Hematology. (to our study with Emel Başak Gencer)
43. Young Participant Award, by Turkish Society of Hematology. (to our study with Zeynep Çakır)
44. Young Participant Award, by Turkish Society of Hematology. (to our study with Melis Kartal)
2008
45. Carreer Project, by The Scientific and Technical Research Council of Turkey
46. Science Award, by Volunteer Educators Association
2007
47. Best Thesis Award of the Year, by Middle East Technical University.
48. Young Participant Award, by Turkish Society of Hematology. (to our study with Tolga Uyuklu)
2006
49. Travel Grant, by European Hematology Association
50. Novartis Oncology Industry Award, by Turkish Society of Hematology
51. Young Participant Award, by Turkish Society of Hematology.
2005
52. NATO-A2 scholarship, (Medical University of South Caroline, SC-USA, 2005-2006).
53. MS and Phd Scholarship, by Higher Education Council of Turkey (1999-2006)
54. More than 80 publication award by Higher Education Council of Turkey, Turkish Society of Hematology, Middle East Technical University, and Izmir Institute of Technology.

Research Tags
Cancer Biology, Drug Resistance, Signaling Pathways, Science and Technology Policies.
Bio

Prof. Dr. Yusuf BARAN
Dr. Yusuf Baran has been working as a full professor at Abdullah Gul University, Faculty of Life and Natural Sciences, Department of Molecular Biology and Genetics. After receiving his bachelor degree in Dicle University, Department of Biology between 1994-1998, he earned his M.Sc. and Ph.D. degrees in 2002 and 2006, respectively, in the Middle East Technical University, Faculty of Science, Department of Biological Sciences. During his Ph.D. studies, he was awarded with the NATO-A2 scholarship provided by NATO, and got the chance to continue his research in the United States of America, Medical University of South Carolina, Hollings Cancer Center, Department of Biochemistry and Molecular Biology for 6 months (2005 July-2006 February). Dr. Yusuf Baran has been involved in more than twenty scientific research projects supported by national and international organizations. Dr. Yusuf Baran has authored or co-authored in 80 papers in peer-reviewed journals, he has given more than 100 invited talks in national and international meetings and conferences, is the author of 5 book chapters. His scientific achievements has been recognized and awarded by national and international accredited institutions holding more than 100 awards. Selected ones are “Outstanding Young Scientist Award” by Turkish Academy of Sciences in 2010 and "2013 Young Scientist" by World Economic Forum (WEF) in 2013. This honor by WEF is bestowed each year to recognize the most distinguished science leaders under the age of 40, nominated from around the world. Dr Baran’s selection is in recognition of his record of scientific excellence, his commitment to society and potential to contribute to transforming the world through his scientific knowledge. He was also elected as "Outstanding Young Person of Turkey in Scientific Leadership", by International Young Leaders and Entrepreneurs in 2013.
He is also a member of Executive Committee of The Scientific and Technical Research Council of Turkey and Global Young Academy. Currently, he is the dean of Faculty of Life and Natural Sciences and head of Department of Molecular Biology and Genetics at Abdullah Gul University. In his research, Dr. Baran focused on molecular biology of cancer, molecular hematology, multidrug resistance mechanisms, reversal of resistance, apoptosis, the involvement of bioactive sphingolipids in apoptosis and drug resistance, combination therapies, signalling pathways.

General and Contact Information

Title
Prof.
First Name
Yusuf
Last Name
Baran
Date of Birth
11/12/1977
Country of Origin
Turkey
Country of Residence
Turkey
City
Kayseri
Your Website
www.yusufbaran.net
Languages
English, Turkish

History

Member for
1 year 38 weeks
Blog
View recent blog entries